PR94176

PHILADELPHIA, Jan. 24, 2022 /PRNewswire=KYODO JBN/ --

-- Surpasses 900 trials across 65 countries, expands leadership team and

product offerings, and posts another year of 30% growth, all while maintaining

an exceptional performance level.

Suvoda, LLC (

https://c212.net/c/link/?t=0&l=en&o=3418408-1&h=381713011&u=https%3A%2F%2Fwww.suvoda.com%2F%3Futm_source%3Dpress-release%26utm_medium%3Dweb%26utm_content%3Dsuvoda-exceeds-targets-2021&a=Suvoda

) , a global clinical trial technology company that specializes in highly

complex studies, such as oncology, central nervous system (CNS) and rare

disease, today announced that 2021 was another record year, exceeding its

bookings targets and expanding its reach by supporting complex clinical trials

in 65 countries. As clinical trial sponsors and CROs have had to adapt to

pandemic realities, offering hybrid or even fully remote trials, Suvoda quickly

accelerated its roadmap plans to build on its IRT flagship solution (

https://c212.net/c/link/?t=0&l=en&o=3418408-1&h=1322830053&u=https%3A%2F%2Fwww.suvoda.com%2Fproducts%2Firt-ti%3Futm_source%3Dpress-release%26utm_medium%3Dweb%26utm_content%3Dsuvoda-exceeds-targets-2021&a=IRT+flagship+solution

), offering an integrated eConsent solution, now in the early adopter phase,

and with plans to offer an integrated eCOA solution in 2022.

Logo - https://mma.prnewswire.com/media/1039295/Suvoda_Logo.jpg

"2021 saw tremendous advancements in the clinical trial space, while also

putting unprecedented pressure on those who manage them, especially those

trials that bring life-sustaining treatments to patients around the world,"

said Jagath Wanninayake, CEO of Suvoda. "The ability to handle these

complexities is inherent in our products and services. We are proud that we

have been able to alleviate some of that burden for our customers and look

forward to expanding that support through our unified products as trial

sponsors and CROs look for solutions to the challenges of today's trials."

Rapid, Controlled Expansion

In 2021, Suvoda added 170 employees worldwide, including making two

significant, strategic additions to its executive leadership team. E.K. Koh

joined as Chief Product Officer and Elena Filimonova as Chief Marketing

Officer. Both were selected for their deep experience in scaling global B2B

tech organizations. Following the appointment in 2020 of Yuko Fukasaku as

Suvoda Japan President, the company officially opened its Tokyo office in 2021

and, in the same year, saw its first Asian-based trial using Suvoda IRT go live

for a Japanese sponsor.

Focus Fuels Success  

Suvoda reported 30% growth in bookings compared to 2020 and is on track to

surpass 1,000 trials by the end of this quarter. According to the Tufts Center

for the Study of Drug Development, the number of investigational products

targeting cancer has nearly quadrupled since 2000. Complexity is also on the

rise. In fact, the level of complexity in oncology, CNS and rare disease trials

is increasing dramatically due to myriad factors, including a move to hybrid

trials. Suvoda attributes its success to its laser focus on complex trials, its

superior level of customer service and support, and its well-prepared people.

Despite the incredible pace of change and growth, Suvoda has remained committed

to its values and rigorously-defined processes, and as such, the company has

continued to:

    -- maintain a customer satisfaction score of 9 out of 10;

    -- meet 100% on time delivery for customer acceptance;

    -- deliver the cleanest IRT system in the industry with 0.5 average UAT

       defects; and

    -- complete implementations for complex trials within four to six weeks.

"Change is inevitable, which is why we design our services and support teams to

bring expertise and consistency to each and every complex clinical trial," said

Rob Hummel, chief operating officer of Suvoda. "As we move into 2022, we are

looking forward to continuing to bring steady, measured, yet urgent support to

our sponsors, CROs and partners so they have the data they need, no matter the

patient location, to make informed decisions fast."

-Tufts Center for the Study of Drug Development, Impact Report, Analysis and

Insight Into Critical Drug Development Issues, Volume 23, Number 3, May/June

2021

About Suvoda

Suvoda is a global clinical trial technology company that specializes in highly

complex, life-sustaining studies in therapeutic areas like oncology, central

nervous system (CNS), and rare disease. Founded in 2013 by experts in eClinical

technologies, Suvoda empowers clinical trial professionals to manage the most

urgent moments in the most urgent trials through advanced software solutions

delivered on a single platform. Headquartered outside Philadelphia, Suvoda also

maintains offices in Portland, OR, Barcelona, Spain, Bucharest, Romania and

Tokyo, Japan. The company consistently boasts customer satisfaction scores of 9

out of 10 and has been selected by trial sponsors and CROs to support more than

1000 trials across 65 countries. To learn more, visit www.suvoda.com. Follow

Suvoda on Twitter (

https://c212.net/c/link/?t=0&l=en&o=3418408-1&h=156413549&u=https%3A%2F%2Ftwitter.com%2FSuvodaIRT&a=Twitter

)  and LinkedIn (

https://c212.net/c/link/?t=0&l=en&o=3418408-1&h=2852999794&u=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fsuvoda%2Fmycompany%2F&a=LinkedIn

).

SOURCE Suvoda LLC

CONTACT: Deb Massa, Suvoda, dmassa@suvoda.com, 610.241.2170